Comparison of the in vitro antiproliferative effects of five immunosuppressive drugs on lymphocytes in whole blood from cats

OBJECTIVE: To compare the in vitro immunosuppressive effects of cyclosporine and 4 novel immunosuppressive drugs on lymphocytes in whole blood collected from healthy cats. SAMPLE POPULATION: Whole blood samples collected from 10 healthy adult domestic shorthair cats. PROCEDURE: Mitogen-stimulated lymphocyte proliferation in whole blood incubated with and without various concentrations of cyclosporine, tacrolimus, sirolimus, mycophenolic acid (MPA), or A771726 was measured by use of [3H]thymidine incorporation. Drug concentrations that resulted in a 50% inhibition of mitogen-induced proliferation (IC50) were calculated. Lymphocyte viability was determined by use of the trypan blue dye exclusion method. RESULTS: An obvious dose-response relationship for the antiproliferative effects of each drug was detected. Mean IC50 determined with concanavalin A was 46 nM for cyclosporine, 9 nM for tacrolimus, 12 nM for sirolimus, 16 nM for MPA, and 30 mM for A771726, whereas with pokeweed mitogen, mean IC50 was 33 nM for cyclosporine, 5 nM for tacrolimus, 15 nM for sirolimus, 14 nM for mycophenolic acid, and 25 mM for A771726. Mitogen-stimulated and nonstimulated lymphocytes remained viable, regardless of drug evaluated. CONCLUSIONS AND CLINICAL RELEVANCE: Tacrolimus, sirolimus, MPA, and A771726 inhibited in vitro mitogen-stimulated proliferation of feline lymphocytes in a dose-dependent manner. These novel immunosuppressive drugs may be useful for management of immune-mediated inflammatory diseases and prevention and treatment of rejection in cats that undergo organ transplantation.     

抗旱保水剂在紫花苜蓿种植中应用的试验报告

用抗旱保水剂对土壤和紫花苜蓿种子处理后,进行种植试验。结果表明,使用抗旱保水剂出苗每平方米较对照地增加24.25株,存苗增加35.62株,苗高平均增加0.32cm,根长平均增长0.69cm,鲜草每平方增加0.41kg。     

Production losses in Merino ewes and financial penalties caused by trichostrongylid infections during winter and spring

SUMMARY: The productivity of Merino ewes treated with ivermectin and a controlled-release capsule containing albendazole was compared with untreated ewes grazing the same pastures on each of 3 farms. Treated breeding ewes had significantly increased greasy fleece weights (GFW, 6.5% and 7.1%) compared with untreated breeding ewes, on 2 of 3 farms but treatment caused no significant increase in the GFW of non-breeding ewes. Other benefits of treatment on all farms were a significant increase in body weight gain (from 1.7 to 3.7 kg) and a significant decrease in the weight of dag removed at crutching (from 42 to 622 g). These benefits occurred despite the presence on each farm of worms resistant to benzimidazoles. One disadvantage of treatment was an increase in mean fibre diameter of wool from treated ewes of from 0.12 to 0.41 μm. This increase reduces the value of the wool. Partial budgets indicated a net loss of from 8 to 62 cents per ewe for treatment. However, potential benefits such as increased growth rate and wool production from lambs of treated ewes were not included in the analysis. On one farm ewes were classified as ‘susceptible’ to severe dag if they had a dag score ≥ 4 at the time of capsule treatment. Ewes classified as ‘susceptible’ were about 7 times more likely to develop severe dag than were other ewes. There was no significant difference between the GFW of untreated ‘susceptible’ ewes and untreated ewes not classified as ‘susceptible’. Additionally, the response of GFW to treatment was no different to the response seen in ewes that were not classified as ‘susceptible’. The direct cost of diarrhoea and dag formation in Merino ewes was estimated to be 18, 30, 53, 86, 98 and 145 cents per head for ewes with a dag score of 0, 1, 2, 3, 4 and 5, respectively. This cost did not include potential benefits from reduced risk of breech strike, or intangible benefits associated with the improved welfare of sheep.     

Studies on the biology of black mould (Aspergillus niger) on temperate and tropical onions. 2. The effect of treatments on the control of seedborne A. niger

Treatment of A. niger -inoculated onion seed with benomyl dust (1 g a.i./kg), or a foliar spray of thiram (0·4% a.i./ha) applied to plants grown from inoculated seed under temperate (UK) conditions reduced the incidence of A. niger in harvested crops. Treatment of naturally contaminated Sudanese onion seed with a benomyl + thiram mixture at a rate of 2·5 + 2·5 g a.i./kg or soaking the seed in hot water (15 min at 60°C) reduced the incidence of black mould on bulbs grown in the Sudan in field soil that had not previously been used for onion production. The seed treatments were less effective in crops produced in fields regularly used for onion production. However, incubation of harvested bulbs in moist chambers showed that damage to the internal storage tissue of onion bulbs caused by A. niger was reduced by seed treatment.     

Production responses and cost-benefit of long-acting pre-lambing anthelmintic treatment of yearling ewes in two commercial flocks in New Zealand

AIMS: To investigate the production responses and cost-benefit of administering a controlled-release anthelmintic capsule (CRC) to pregnant yearling ewes prior to lambing.

METHODS: Yearling ewes from two commercial sheep flocks (A, n=489; B, n=248) in the North Island of New Zealand were enrolled in the study. Prior to lambing, CRC containing albendazole and abamectin were administered to half the ewes while the other half remained untreated. Ewe liveweights and body condition scores were measured prior to lambing, at weaning and, for Flock B, prior to subsequent mating. Lambs were matched to dams shortly after birth and the weight and number of lamb weaned per ewe were determined. A cost-benefit analysis was undertaken for Flock B considering the increased weight of lamb weaned per ewe, and the weight of ewes at the next mating and the benefit in terms of lambs born.

RESULTS: The mean weight at weaning of treated ewes was greater for treated than untreated ewes by 2.76 (95% CI 0.64–4.88)?kg in Flock A (p<0.001) and 2.35 (95% CI ?0.41–5.12)?kg in Flock B (p=0.003); the weight of lamb weaned per ewe was greater for treated than untreated ewes by 1.43 (95% CI ?0.71 to –3.49)?kg in Flock A (p=0.041) and 3.97 (95% CI 1.59–6.37)?kg in Flock B (p<0.001), and ewe liveweight prior to subsequent mating was greater for treated than untreated ewes in Flock B by 4.60 (95% CI 3.6–5.6)?kg (p<0.001). There was no difference in the percentage of lambs reared to weaning between treated and untreated ewes in either flock (p>0.8). The overall cost-benefit of treatment for Flock B was NZ$9.44 per treated ewe.

CONCLUSIONS AND CLINICAL RELEVANCE: Pre-lambing CRC administration to yearling ewes resulted in increased ewe weaning weights and weight of lamb weaned in both the flocks studied. There was an economic benefit in the one flock where this was assessed.     

Use of the food animal residue avoidance databank

In its extra-label drug use policy, the FDA states, as one of the criteria for permitting extra-label drug use, that a significantly extended time period be assigned for drug withdrawal prior to marketing meat, milk or eggs. The phrase "significantly extended time period" is taken to mean, at minimum, the amount of time necessary for any drug residues to deplete to subtolerance levels; however, determination of this period is left to the discretion of the veterinarian responsible for the extra-label drug use. The extended period will vary for each drug, dose, species, and route of administration. Therefore, it is unrealistic to assume that the practitioner can make a rational determination of extended drug withdrawal times without more information than is available through textbooks and professional journals. FARAD was specifically designed to provide veterinarians with the information required to determine extended withdrawal times, and thus prevent residues when drugs are used in an extra-label manner. FARAD can provide valuable residue avoidance assistance to veterinarians when drugs are administered in an extra-label manner, but it is not the answer to the national drug residue problem. Most residues result from failure to observe label-recommended withdrawal times, whereas less than 20% are thought to result from extra-label drug use. A substantial armamentarium of approved drugs is available to the veterinarian to treat most diseases in beef cattle, swine, and broiler chickens; thus, extra-label drug use in these species is unnecessary under most conditions.(ABSTRACT TRUNCATED AT 250 WORDS)     

Plasma pharmacokinetics of midazolam in chickens, turkeys, pheasants and bobwhite quail

In vivo plasma pharmacokinetics of midazolam hydrochloride (5 mg/kg i.v.) were determined in commercially raised broiler chickens, turkeys, ring-necked pheasants and bobwhite quail. Pharmacokinetic profiles of midazolam were similar for all four species, especially with regard to the area under the plasma drug concentration-time curve. Estimates of the half-life of elimination of midazolam were 0.42, 1.45, 1.90, and 9.71 h for turkeys, chickens, bobwhite quail, and pheasant, respectively. This was similar to the major metabolite (1-hydroxymidazolam). Elimination half-lives for 1-hydroxymidazolam were 1.35, 1.86, 1.97, and 13.97 h for turkey, chicken, bobwhite quail and pheasant, respectively. Elimination half-lives for 4-hydroxymidazolam were 0.76, 1.23, 2.85, and 13.82 h for chicken, turkey, pheasant, and bobwhite quail, respectively. In addition to traditional pharmacokinetic approaches to parameter estimation, a bootstrapping technique was employed to attempt to achieve more realistic approximations of the concentrations at later time-points.